
Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Cervical Cancer
- Head and Neck Oncology
- Hematology
- General Oncology
- Urological Cancers
- Gastrointestinal Cancer
- Brain and Spinal Cord Cancer
- Endometrial Cancer
Abstract
Citation: Clin Oncol. 2024;9(1):2120.DOI: 10.25107/2474-1663-v9-id2120
Serum Concentrations of IL-17 and IL-22 as Possible Biomarkers of Hepatocellular Carcinoma
Stromar IK, Sirotkovic-Skerlev M, Plavetic ND, Sedlic F, Oreskovic I, Kulic J, Majerovic M, Gojevic A, Premuzic M, Plestina S, Krznaric Z, Potocki Sand Kulic A
Department of Internal Medicine, Division of Gastroenterology and Hepatology, University Hospital Center Zagreb, Croatia Department of Pathophysiology, School of Medicine, University of Zagreb, Croatia Department of Oncology, University Hospital Centre Zagreb, Croatia School of Medicine, University of Zagreb, Croatia Department of Surgery, University Hospital Center Zagreb, Croatia Department of Medical Chemistry, Biochemisty and Clinical Chemistry, School of Medicine, University of Zagreb, Croatia Department of Oncology, Division of Pathophysiology and Experimental Oncology, University Hospital Center Zagreb, Croatia
*Correspondance to: Maja Sirotković-Skerlev
PDF Full Text Research Article | Open Access
Abstract:
Background: In the majority of patients, Hepatocellular Carcinoma (HCC) develops from liver cirrhosis, but the developed cirrhosis is not necessary for the development of HCC. At this time, there are no reliable blood-based biomarkers that could identify the malignant transformation in liver parenchyma. We examined whether serum concentrations of IL-17 and IL-22 proteins could be used to point out patients with liver disease, fibrosis, or cirrhosis who have possibly developed HCC. Methods: This study included 198 patients and 28 Healthy Controls (HC). The study included 33 patients with HCC, 51 with liver cirrhosis and no morphological signs for HCC, 43 with viral hepatitis B or C, 50 with autoimmune liver disease, and 21 with non-alcoholic fatty liver disease without cirrhosis. Concentrations of IL-17 and IL-22 in sera were determined by Enzyme-Linked Immunosorbent Assay (ELISA). Results: Serum concentrations of IL-17 and IL-22 were significantly higher in patients with liver diseases than in control patients. Patients with liver cirrhosis had significantly higher IL-17 and IL-22 concentrations than other liver diseases. Notably, both IL-17 and IL-22 were significantly higher in patients with liver cirrhosis than those with hepatocellular carcinoma. IL-17 and IL-22 were significantly positively correlated in all types of liver diseases except hepatocellular carcinoma. Conclusion: Based on the differences in concentration of IL-17 and IL-22 in sera of patients with liver diseases and healthy controls, and then patients with LC and HCC, those interleukins are emerging as possible candidates for biomarkers that could be used to identify an occurrence of HCC.
Keywords:
Liver; Inflammation; Cirrhosis; Hepatocellular carcinoma; Interleukin-17; Interleukin-22; Croatian caucasian population
Cite the Article:
Stromar IK, Sirotkovic-Skerlev M, Plavetic ND, Sedlic F, Oreskovic I, Kulic J, et al. Serum Concentrations of IL-17 and IL-22 as Possible Biomarkers of Hepatocellular Carcinoma. Clin Oncol. 2024; 9: 2120..